After the successful completion of the BLISS-LN trial and previewing the results at EULAR 2020 and ACR Convergence, GlaxoSmithKline announced yesterday that the FDA has approved belimumab (Benlysta) for use in adults with active lupus nephritis (LN) receiving background/standard therapy.
All News
Gilead Sciences Inc announced yesterday that it has decided not to pursue the an rheumatoid arthritis (RA) indicatin for its once daily oral JAK inhibitor, filgotinib (also named Jyseleca).
A steering committee and task force was convened to develop recommendations for the use of Janus kinase (JAK) inhibitors in the treatment of immune-mediated inflammatory diseases (IMID).
Lung cancer risk is often increased with inflammation and autoimmune disease; a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
The SELECT-PsA 2 trial was presented at the ACR meeting and recently published in Annals of Rheumatic Disease, shows that psoriatic arthritis (PsA) patients who have failed at least one biologic DMARD, did respond well to upadacitinib.
The results of the long awaited PIANO study have been reported in the journal Gastroenterology, showing that pregnant women with IBD may safely receive biologic or thiopurine therapy throughout the pregnancy without substantial added risk to the unborn or mother.
This podcast features a discussion of autoinflammatory and Still's disease abstracts from virtual ACR 2020. Dr. Jack Cush is joined by a panel of experts including Drs. Olga Petryna, Bella Metha and Michael Ombrello.
Dr. Jack Cush reviews a few more ACR 2020 abstracts and presents a new plan to learn or take in ACR20 content.
Dr. Kathryn Dao reviews abstract L04 - Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program - at the 2020 ACR annual meeting.
Here are my highlights from day four, Monday, of the ACR 2020 Convergence.
Vaccine Immunogenicity with Tofacitinib
